These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34212457)

  • 1. Psoriasis caused by pembrolizumab treatment in advanced melanoma: A positive prognostic side effect?
    D'Erme AM; Fidanzi C; Janowska A; Allegrini G; Barbara C; Cupini S; Viacava P; Bagnoni G
    Dermatol Ther; 2021 Sep; 34(5):e15050. PubMed ID: 34212457
    [No Abstract]   [Full Text] [Related]  

  • 2. Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.
    Totonchy MB; Ezaldein HH; Ko CJ; Choi JN
    JAMA Dermatol; 2016 May; 152(5):590-2. PubMed ID: 26675815
    [No Abstract]   [Full Text] [Related]  

  • 3. Rupioid psoriasis induced by pembrolizumab.
    Marti-Marti I; Gómez S; Riera-Monroig J; Carrera C; Mascaró JM
    Indian J Dermatol Venereol Leprol; 2020; 86(5):580-582. PubMed ID: 32719194
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast.
    Takama H; Shibata T; Ando Y; Yanagishita T; Ohshima Y; Akiyama M; Watanabe D
    Eur J Dermatol; 2020 Apr; 30(2):188-190. PubMed ID: 32538362
    [No Abstract]   [Full Text] [Related]  

  • 5. New Yellow Plaques in a Patient Taking Pembrolizumab.
    Massey PR; Jones KM; Fox MC
    JAMA Oncol; 2017 Jan; 3(1):119-120. PubMed ID: 27892986
    [No Abstract]   [Full Text] [Related]  

  • 6. Dupilumab-induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression.
    Ahmad M; Murphy MJ; Damsky W; Leventhal J
    Int J Dermatol; 2023 Aug; 62(8):e424-e426. PubMed ID: 36468831
    [No Abstract]   [Full Text] [Related]  

  • 7. Pembrolizumab: a new Drug That Can Induce Exacerbations of Psoriasis.
    Sahuquillo-Torralba A; Ballester-Sánchez R; Pujol-Marco C; Botella-Estrada R
    Actas Dermosifiliogr; 2016 Apr; 107(3):264-6. PubMed ID: 26546027
    [No Abstract]   [Full Text] [Related]  

  • 8. A Case of Ixekizumab-induced Psoriasiform Eruption.
    Oiwa T; Fujita M; Takase S; Nishimura Y; Ota M; Okada K; Tachibana T
    Acta Derm Venereol; 2019 Apr; 99(4):446-447. PubMed ID: 30723870
    [No Abstract]   [Full Text] [Related]  

  • 9. Psoriasis and Palmoplantar Pustulosis Following Pembrolizumab Therapy Successfully Treated With Topical Tapinarof Cream 1.
    Kaiser M; Jaalouk D; Issa NT
    J Drugs Dermatol; 2024 Feb; 23(2):103-104. PubMed ID: 38306132
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab induced de novo rupoid psoriasis: A rare cutaneous manifestation of immune checkpoint inhibitors.
    Mohta A; Arora A; Jain SK
    J Cosmet Dermatol; 2022 May; 21(5):2005-2008. PubMed ID: 35231155
    [No Abstract]   [Full Text] [Related]  

  • 12. Follicular psoriasis induced by pembrolizumab in a patient with advanced non-small-cell lung cancer.
    Scarfì F; Lacava R; Patrizi A; Tartari F; Ravaioli GM; Veronesi G; Lambertini M; Dika E
    Int J Dermatol; 2019 Aug; 58(8):e151-e152. PubMed ID: 30964199
    [No Abstract]   [Full Text] [Related]  

  • 13. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis.
    Wendling D; Letho-Gyselinck H; Guillot X; Prati C
    J Rheumatol; 2012 Mar; 39(3):657. PubMed ID: 22383356
    [No Abstract]   [Full Text] [Related]  

  • 14. Superficial thrombophlebitis during secukinumab treatment in a patient with psoriasis.
    Mammadli K; Ceken K; Unal B; Karakas AA; Yilmaz E; Alpsoy E
    Indian J Dermatol Venereol Leprol; 2020; 86(6):699-701. PubMed ID: 33037163
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
    Robert C; Hwu WJ; Hamid O; Ribas A; Weber JS; Daud AI; Hodi FS; Wolchok JD; Mitchell TC; Hersey P; Dronca R; Joseph RW; Boutros C; Min L; Long GV; Schachter J; Puzanov I; Dummer R; Lin J; Ibrahim N; Diede SJ; Carlino MS; Joshua AM
    Eur J Cancer; 2021 Feb; 144():182-191. PubMed ID: 33360855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report.
    Currado D; Margiotta D; Conforti C; Coppola R; Panasiti V; Afeltra A; Navarini L
    Scand J Rheumatol; 2020 Jan; 49(1):75-76. PubMed ID: 31262212
    [No Abstract]   [Full Text] [Related]  

  • 17. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy.
    Hay RA; Pan JY
    Clin Exp Dermatol; 2014 Aug; 39(6):751-2. PubMed ID: 24984757
    [No Abstract]   [Full Text] [Related]  

  • 18. Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma.
    Hu JB; Ravichandran S; Rushing C; Beasley GM; Hanks BA; Jung SH; Salama AKS; Ho L; Mosca PJ
    Anticancer Res; 2020 Sep; 40(9):5245-5254. PubMed ID: 32878813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker.
    Younis S; Rimar D; Slobodin G; Rosner I
    J Rheumatol; 2012 Oct; 39(10):2055-6. PubMed ID: 23028035
    [No Abstract]   [Full Text] [Related]  

  • 20. Adalimumab-induced psoriasis in a patient with Crohn's disease.
    Korkmaz U; Duman AE; Dindar G; Yilmaz H; Dursun IH; Celebi A; Senturk O; Hulagu S
    Indian J Gastroenterol; 2013 Mar; 32(2):135-6. PubMed ID: 23151897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.